Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094768 | 0.89 | OPRD1 (0.44) | OPRD1KCNH2MRGPRX2CYP2D6 | |
| SCHEMBL5097411 | 0.88 | MEN1 (0.41) | OPRD1KCNH2CYP2D6SLC6A4 | |
| SCHEMBL5197449 | 0.84 | PLAU (0.33) | — | |
| SCHEMBL5090846 | 0.81 | OPRD1 (0.43) | OPRD1KCNH2MRGPRX2CYP2D6 | |
| SCHEMBL5097270 | 0.81 | KDM4E (0.37) | OPRD1KCNH2CYP2D6 | |
| SCHEMBL27687211 | 0.79 | CNR1 (0.33) | — | |
| SCHEMBL5090991 | 0.78 | OPRD1 (0.42) | OPRD1KCNH2CYP2D6SLC6A4 | |
| SCHEMBL5097281 | 0.77 | OPRD1 (0.44) | OPRD1KCNH2CYP2D6 | |
| SCHEMBL490270 | 0.76 | OPRD1 (0.48) | OPRD1KCNH2MRGPRX2CYP2D6 | |
| SCHEMBL4519813 | 0.76 | OPRD1 (0.45) | OPRD1KCNH2MRGPRX2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | claimed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006121887-A2 | IMPLANTABLE MATERIALS AND METHODS FOR INHIBITING TISSUE ADHESION FORMATION | COOK BIOTECH INCORPORATED (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885MRGPRX2 184/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885MRGPRX2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.